SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Dino's Bar & Grill

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Goose94 who wrote (83475)5/1/2020 9:21:58 AM
From: Goose94Read Replies (1) of 203329
 
Centric Health (CHH-V) Cormark Securities analyst Kyle McPhee began coverage on Centric Health with a "buy" rating and 35-cent share target, matching the consensus on the Street.

Mr. McPhee says in a note: "CHH is sitting in a good spot. The company is facing a sustained path of organic growth and consolidation as the leader in a secular growth sector (institutional pharmacy services to senior living facilities in Canada).

Additionally, for the first time in a long time, CHH faces this path without the shackles of debt overload and bloated opex. The revitalized company profile exists on the back of a turnaround plan delivered by President/CEO David Murphy who joined in May, 2018, followed by a series of moves that included segment divestment, cost cutting, capital raises and debt reduction.

The market is starting to take notice with the stock rallying over the last month. Despite the move, we think the stock still fails to reflect all value for the extent of the opportunity, notably the abundance of organic bed addition opportunities and FCF leverage as EBITDA expands."
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext